Precipio (NASDAQ:PRPO) Announces Quarterly Earnings Results

Precipio (NASDAQ:PRPO) posted its earnings results on Thursday. The biotechnology company reported ($0.81) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $6.71 million during the quarter. Precipio had a negative net margin of 3.57% and a negative return on equity of 6.81%.

Precipio Trading Down 9.0%

Shares of PRPO stock traded down $2.56 during trading hours on Friday, hitting $26.04. The company had a trading volume of 41,456 shares, compared to its average volume of 37,501. The company’s fifty day moving average is $27.84 and its 200 day moving average is $24.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.61 and a quick ratio of 1.36. Precipio has a fifty-two week low of $7.31 and a fifty-two week high of $33.63. The stock has a market capitalization of $46.48 million, a PE ratio of -55.40 and a beta of 1.38.

Hedge Funds Weigh In On Precipio

Large investors have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new position in shares of Precipio in the 3rd quarter worth approximately $194,000. Renaissance Technologies LLC lifted its holdings in shares of Precipio by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares during the last quarter. Evernest Financial Advisors LLC acquired a new position in shares of Precipio in the 3rd quarter worth approximately $374,000. Geode Capital Management LLC lifted its holdings in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the last quarter. Finally, Topline Capital Management LLC acquired a new position in shares of Precipio in the 3rd quarter worth approximately $1,158,000. 10.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on PRPO shares. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.